TARDBP and proteostasis deficiencies: Although studies are needed to assess if the above proposition still stands in ALS selectively vulnerable MNs and in in vivo ALS experimental settings, NCL seems a promising means to understand the mechanisms of TDP-43-associated proteinopathies and a possible therapeutic target for ALS and related disorders.